Type 2 Diabetes – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Type 2 Diabetes – Pipeline Review, H1 2020’, provides an overview of the Type 2 Diabetes pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Type 2 Diabetes, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Type 2 Diabetes and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Type 2 Diabetes

– The report reviews pipeline therapeutics for Type 2 Diabetes by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Type 2 Diabetes therapeutics and enlists all their major and minor projects

– The report assesses Type 2 Diabetes therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Type 2 Diabetes

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Type 2 Diabetes

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Type 2 Diabetes pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3SBio Inc

Adare Pharmaceuticals Inc

ADM Therapeutics

Adocia SAS

Aerami Therapeutics

Afimmune Biopharma Ltd

AgeX Therapeutics Inc

Akero Therapeutics Inc

Akston Biosciences Corp

Algiax Pharmaceuticals GmbH

Alms Therapeutics

AlphaMab Co Ltd

Amgen Inc

AmideBio LLC

Anji Pharmaceuticals Inc

AnyGen Co Ltd

Apcegen Technologies Pvt Ltd

Aphios Corp

Apoglyx AB

APT Therapeutics Inc

Aptamer Sciences Inc

AptamiR Therapeutics Inc

Arena Pharmaceuticals Inc

Ariddad Therapeutics SL

Arkay Therapeutics LLC

Artery Therapeutics Inc

AsiaBiome

Astellas Pharma Inc

AstraZeneca Plc

Atrogi AB

Auritec Pharmaceuticals Inc

Avolynt Inc

Beijing Eastern Biotech Co Ltd

Betagenon AB

Betta Pharmaceuticals Co Ltd

Biocon Ltd

BioEos Ltd

Biogenomics Ltd

BioKier Inc

BioLingus AG

BioRestorative Therapies Inc

Biozeus Pharmaceutical SA

Boehringer Ingelheim International GmbH

Boryung Pharmaceutical Co Ltd

Boston Therapeutics Inc

Braasch Biotech LLC

BrightGene Bio-Medical Technology Co Ltd

Buto Biopharma Inc

C4X Discovery Holdings Plc

Cadila Healthcare Ltd

Cadila Pharmaceuticals Ltd

Caelus Health

Caldan Therapeutics Ltd

CAR-T (Shanghai) Biotechnology Co Ltd

Carlina Technologies SAS

Carmot Therapeutics Inc

Cellix Bio Pvt Ltd

Celon Pharma SA

Centaurus Therapeutics Inc

Center Laboratories Inc

CGeneTech (Suzhou China) Co Ltd

Chain Biotechnology Ltd

Chengdu Di'ao Pharmaceutical Group Co Ltd

Chengdu Easton Biopharmaceuticals Co Ltd

Chipscreen Biosciences Ltd

Chong Kun Dang Pharmaceutical Corp

Chongqing Chenan BioPharm Co Ltd

Chongquing Conquer Pharmaceutical Co Ltd

Chugai Pharmaceutical Co Ltd

Cinnagen Co

CJ HealthCare Corp

CohBar Inc

Coherus BioSciences Inc

Concenter BioPharma Silkim Ltd

Corbus Pharmaceuticals Inc

CRISPR Therapeutics AG

Cryno LLC

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co Ltd

D&D Pharmatech Co Ltd

Daewoong Pharmaceutical Co Ltd

Daiichi Sankyo Co Ltd

Delpor Inc

Diabetology (Products) Ltd

Diamyd Medical AB

Diapin Therapeutics LLC

Diasome Pharmaceuticals Inc

DiscoveryBiomed Inc

DNJ Pharma Inc

DNX Biopharmaceuticals Inc

Dong-A Socio Holdings Co Ltd

EastGate Pharmaceuticals Inc

Elevian Inc

Eli Lilly and Co

Emerald Organic Products Inc

Emmaus Life Sciences Inc

Empros Pharma AB

EncuraGen Inc

Endece LLC

Energenesis Biomedical Co Ltd

Enesi Pharma Ltd

Enteris BioPharma Inc

Enzene Biosciences Ltd

Enzo Biochem Inc

Eternygen GmbH

Evotec SE

F. Hoffmann-La Roche Ltd

Fairbanks Pharmaceuticals Inc

Fochon Pharma Inc

Forkhead BioTherapeutics Inc

FortuneRock (China) Ltd

Gan & Lee Pharmaceutical Ltd

Generex Biotechnology Corp

Genexine Inc

Genovate Biotechnology Co LTD

Genprex Inc

Geropharm

Gilead Sciences Inc

GL Pharm Tech Corp

Glaceum Inc

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

Glucox Biotech AB

Gmax Biopharm Ltd

Guangdong Zhongsheng Pharmaceutical Co Ltd

Gubra ApS

Handok Inc

Hangzhou East China Pharmaceutical Group Co Ltd

Hangzhou Jiuyuan Gene Engineering Co Ltd

Hanmi Pharmaceuticals Co Ltd

HEC Pharm Co Ltd

Hefei Industrial Pharmaceutical Institute Co Ltd

Hengrui Therapeutics Inc

Housey Pharmaceutical Research Laboratories LLC

HSRx Group

Hua Medicine Shanghai Ltd

Huons Co Ltd

Hyundai Pharma Co Ltd

Ildong Pharmaceutical Co Ltd

Immupharma Plc

Immuron Ltd

Impetis Biosciences Ltd

Inflammasome Therapeutics Inc

Inflazome Ltd

Innovimmune Biotherapeutics Inc

Inspyr Therapeutics Inc

InStar Technologies AS

Intarcia Therapeutics Inc

Integral Molecular Inc

Ionis Pharmaceuticals Inc

Japan Tobacco Inc

Jeil Pharmaceutical Co Ltd

Jiangsu Chia-tai Tianqing Pharmaceutical Co Ltd

Jiangsu Hansoh Pharmaceutical Group Co Ltd

Jiangsu Hengrui Medicine Co Ltd

Jiangsu T-mab BioPharma Co Ltd

Johnson & Johnson

Jortan Pharmaceuticals Inc

Kadimastem Ltd

Kaneq Bioscience Ltd

KB Biomed Inc

Kissei Pharmaceutical Co Ltd

Klotho Therapeutics Inc

Kowa Co Ltd

Kriya Therapeutics

Laboratorios Silanes SA de CV

Lannett Co Inc

Lead Discovery Center GmbH

Leading BioSciences Inc

Lexicon Pharmaceuticals Inc

LG Chem Ltd

Lin Bioscience Inc

LipimetiX Development Inc

Lixte Biotechnology Holdings Inc

Longevity Biotech Inc

Lotus Pharmaceutical Co Ltd

Luye Pharma Group Ltd

Lyndra Inc

MannKind Corp

MD Healthcare Inc

Medesis Pharma SA

Medlab Clinical Ltd

Melior Pharmaceuticals I Inc

Merck & Co Inc

Mesoblast Ltd

Metabolic Solutions Development Company LLC

Metabolys SAS

Metacrine Inc

Metavant Sciences Ltd

MetrioPharm AG

Metynex Pharmaceuticals AB

Mito BioPharm LLC

Mitsubishi Tanabe Pharma Corp

Moogene Medi Inc

Naia Ltd

Neuraly Inc

Neurimmune Holding AG

Neurodon LLC

NGM Biopharmaceuticals Inc

Novartis AG

NovaTarg Therapeutics Inc

NovMetaPharma Co Ltd

Novo Nordisk AS

NuSirt Biopharma Inc

NutriBand Inc

Oblique Therapeutics AB

OliPass Corporation

Omeros Corp

OPKO Health Inc

OptiKira LLC

Oramed Pharmaceuticals Inc

Orbsen Therapeutics Ltd

Original BioMedicals Co Ltd

Palatin Technologies Inc

Panorama Research Inc

Paras Biopharmaceuticals Finland Oy

Park Active Molecules

PegBio Co Ltd

Peptron Inc

Pfizer Inc

PharmaCyte Biotech Inc

Pila Pharma AB

Polus Inc

Poxel SA

Precigen Inc

Preveceutical Medical Inc

ProLynx LLC

Prometheon Pharma LLC

Protheragen Inc

Prous Institute for Biomedical Research SA

Purzer Pharmaceutical Co Ltd

QuiaPEG Pharmaceuticals AB

Remd Biotherapeutics Inc

reMYND NV

Reneo Pharmaceuticals Inc

Renova Therapeutics Inc

Rezolute Inc

Rhythm Pharmaceuticals Inc

Ridgeline Therapeutics LLC

Samjin Pharm Co Ltd

Saniona AB

Sanofi

Sanwa Kagaku Kenkyusho Co Ltd

SatRx

SBI Pharmaceuticals Co Ltd

ScandiCure AB

Schrodinger LLC

Sciwind Biosciences Co Ltd

Scohia Pharma Inc

Senseion Inc

Sensulin LLC

Seres Therapeutics Inc

Serodus ASA

Serometrix LLC

Serpin Pharma LLC

Shandong Luye Pharmaceutical Co Ltd

Shanghai Fosun Pharmaceutical (Group) Co Ltd

Shanghai Innogen Pharmaceutical Technology Co Ltd

Shanghai Yingli Pharmaceutical Co Ltd

Shenzhen HighTide Biopharmaceutical Ltd

Shionogi & Co Ltd

Shouyao Holding Co Ltd

Sichuan Haisco Pharmaceutical Co Ltd

Signal Pharma Ltd

Sihuan Pharmaceutical Holdings Group Ltd

Sino Biopharmaceutical Ltd

Sirona Biochem Corp

SJT Molecular Research SL

Sosei Heptares

Stelis Biopharma Pvt Ltd

Sulfateq BV

Suzhou Ribo Life Sciences Co Ltd

Suzuken Co Ltd

Sveikatal Inc

SymbioCellTech LLC

Taisho Pharmaceutical Holdings Co Ltd

Takeda Pharmaceutical Co Ltd

Techfields Pharma Co Ltd

Teijin Pharma Ltd

Theracos Inc

Thermalin Inc

TiumBio Co Ltd

Tonghua Dongbao Pharmaceutical Co Ltd

Torrent Pharmaceuticals Ltd

Transgene Biotek Ltd

Transira Therapeutics LLC

TTY Biopharm Co Ltd

TWi Biotechnology Inc

Twoxar Inc

Uni-Bio Science Group Ltd

United Biomedical Inc

USV Pvt Ltd

Valin Technologies Ltd

ViaCyte Inc

Viking Therapeutics Inc

VitNovo Inc

Vivus Inc

vTv Therapeutics Inc

Vybion Inc

Wuxi Hebang Biotechnology Co Ltd

XERIS Pharmaceuticals Inc

XL-protein GmbH

XOMA Corp

XuanZhu Pharma Co Ltd

Yichang Hec Changjiang Pharmaceutical Co Ltd

Youngene Therapeutics Co Ltd

Yuhan Corp

Zealand Pharma AS

Zhejiang Doer Biologics Corp

Zhejiang Hisun Pharmaceutical Co Ltd

Zhejiang Huayang Pharmaceutical Co Ltd

Zih Yuan Tang Biotechnology Co Ltd

Table of Contents

Table of Contents

Introduction

Type 2 Diabetes - Overview

Type 2 Diabetes - Therapeutics Development

Type 2 Diabetes - Therapeutics Assessment

Type 2 Diabetes - Companies Involved in Therapeutics Development

Type 2 Diabetes - Drug Profiles

Type 2 Diabetes - Dormant Projects

Type 2 Diabetes - Discontinued Products

Type 2 Diabetes - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Type 2 Diabetes, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Type 2 Diabetes – Pipeline by 3SBio Inc, H1 2020

Type 2 Diabetes – Pipeline by Adare Pharmaceuticals Inc, H1 2020

Type 2 Diabetes – Pipeline by ADM Therapeutics, H1 2020

Type 2 Diabetes – Pipeline by Adocia SAS, H1 2020

Type 2 Diabetes – Pipeline by Aerami Therapeutics, H1 2020

Type 2 Diabetes – Dormant Projects, H1 2020

List of Figures

List of Figures

Number of Products under Development for Type 2 Diabetes, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports